Shares

16 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2024

May 15, 2024

SELL
$76.4 - $96.33 $4.19 Million - $5.28 Million
-54,857 Reduced 69.0%
24,644 $2.32 Million
Q4 2023

Feb 14, 2024

BUY
$59.53 - $85.11 $4.73 Million - $6.77 Million
79,501 New
79,501 $6.32 Million
Q1 2023

May 15, 2023

BUY
$43.88 - $52.48 $577,987 - $691,266
13,172 New
13,172 $659,000
Q3 2022

Nov 14, 2022

BUY
$46.84 - $58.49 $624,517 - $779,847
13,333 New
13,333 $710,000
Q1 2022

May 16, 2022

SELL
$44.33 - $57.82 $5.19 Million - $6.77 Million
-117,106 Closed
0 $0
Q4 2021

Feb 14, 2022

SELL
$40.27 - $56.99 $425,613 - $602,327
-10,569 Reduced 8.28%
117,106 $5.2 Million
Q3 2021

Nov 15, 2021

BUY
$47.43 - $84.23 $1.58 Million - $2.8 Million
33,265 Added 35.23%
127,675 $6.15 Million
Q2 2021

Aug 16, 2021

SELL
$73.06 - $97.7 $3.94 Million - $5.27 Million
-53,963 Reduced 36.37%
94,410 $8.01 Million
Q1 2021

May 17, 2021

BUY
$70.43 - $97.42 $10.1 Million - $14 Million
143,877 Added 3200.11%
148,373 $12.5 Million
Q4 2020

Feb 16, 2021

BUY
$48.9 - $75.26 $219,854 - $338,368
4,496 New
4,496 $338,000
Q3 2020

Nov 16, 2020

SELL
$37.23 - $50.97 $1.44 Million - $1.97 Million
-38,600 Closed
0 $0
Q2 2020

Aug 14, 2020

BUY
$28.78 - $46.83 $1.11 Million - $1.81 Million
38,600 New
38,600 $1.48 Million
Q1 2020

May 15, 2020

SELL
$25.53 - $70.14 $3 Million - $8.25 Million
-117,631 Closed
0 $0
Q4 2019

Feb 14, 2020

BUY
$54.18 - $65.64 $6.37 Million - $7.72 Million
117,631 New
117,631 $6.41 Million
Q1 2018

May 15, 2018

SELL
$26.05 - $34.5 $3.16 Million - $4.18 Million
-121,222 Closed
0 $0
Q4 2017

Feb 14, 2018

BUY
$24.5 - $36.01 $2.97 Million - $4.37 Million
121,222
121,222 $3.11 Million

Others Institutions Holding GKOS

About GLAUKOS Corp


  • Ticker GKOS
  • Exchange NYSE
  • Sector Healthcare
  • Industry Medical Devices
  • Shares Outstandng 47,596,900
  • Market Cap $7.18B
  • Description
  • Glaukos Corporation, an ophthalmic medical technology and pharmaceutical company, focuses on the development of novel therapies for the treatment of glaucoma, corneal disorders, and retinal diseases. It offers iStent, iStent inject, iStent inject W micro-bypass stents that enhance aqueous humor outflow inserted in cataract surgery to treat mild-...
More about GKOS
Track This Portfolio

Track Two Sigma Investments, LP Portfolio

Follow Two Sigma Investments, LP and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Two Sigma Investments, LP, based on Form 13F filings with the SEC.

News

Stay updated on Two Sigma Investments, LP with notifications on news.